The germline BRCA1/2 pathogenic variants are widely reported among families with a strong history of breast/ovarian cancer,10, 39, 40 cohort of early‐onset BC patients,41 triple‐negative BC patients,42 pancreatic cancer patients,9 and among patients with prostate cancer.8, 43. Here, BRCA1 is linked to prostate cancer.